New York, June 11, 2026, 13:49 EDT
- Shares of Gelteq Limited were last at $0.805, up around 56% for the session. The stock has bounced from $0.5145 to as much as $2.01 today.
- More than 106 million shares traded hands, jumping from the recent average of about 36,040 shares a day since the listing.
- Cboe posted several GELS volatility pauses Thursday after the stock swung sharply during the session.
Gelteq Limited (NASDAQ: GELS) was among the most volatile small-caps on Thursday. Shares were last at $0.805, about 56% above Wednesday’s close. The stock started near $0.5102 and jumped to an intraday high of $2.01 before retreating, but it stayed sharply higher on the day.
Trading spiked, with volume topping 106 million shares, well beyond Robinhood’s typical daily figure of about 36,040 shares. Market cap was shown at $8.58 million. Robinhood data put the stock’s intraday range between $0.51 and $2.01, and the 52-week range at $0.39 to $2.63.
Volatility rules kept triggering trading halts in Gelteq Limited shares on Nasdaq on June 11. Cboe’s halts page showed multiple GELS “Volatility Pause” entries starting at 11:12:36 ET, with the last one at least as late as 13:17:37 ET. All halt times are in Eastern Time, Cboe said. Cboe Global Markets
The pauses match how the market uses Limit Up-Limit Down, which stops trades in NMS stocks from happening outside set price bands. With LULD, a stock that stays in a limit state for more than 15 seconds triggers a five-minute pause by the primary listing exchange. That pause can get longer. According to Nasdaq Trader, a T5 pause happens when a security moves 10% or more in price over five minutes, leading to a single-stock pause.
The rally went beyond the rest of the market. Nasdaq posted a 1.82% gain at 25,628.30, according to Investing.com’s panel. S&P 500 added 1.31% and the Dow rose 1.67% based on the same snapshot.
Gelteq’s investor-relations site on Tuesday showed its newest press release as the June 4 announcement of a new Center of Excellence in Guangdong Province, China. The company’s SEC filings page listed a June 2 Form 6-K as the latest filing. Gelteq said the new China hub will help with product development, testing, formulation and more commercial work.
China news lands after a run of operational updates. Gelteq said on May 20 it started its first clinical trial for an antiparasitic drug candidate. The trial uses Gelteq technology and is meant to back the company’s plan for an FDA regulatory route for animal use. Back on May 12, Gelteq announced as much as $3.5 million in strategic debt financing to fund commercialization work, clinical trial costs, and revenue efforts.
Gelteq struck a securities purchase agreement with an institutional investor for as much as $3.5 million in two tranches, according to a May 26 SEC filing. The first tranche delivered $1.0 million after a $150,000 original issue discount. That came through a convertible promissory note with $1.165 million principal, 7% annual interest and an 18-month maturity, the filing said.
Gelteq’s trading on Thursday stands out as the company is still in a minimum-bid-price grace period from Nasdaq. A Form 6-K filed March 24 showed Nasdaq alerted Gelteq that its stock stayed under $1.00 for 30 straight business days. That notice gives Gelteq until September 14, 2026, to get back above the minimum. The company needs its closing bid to hit at least $1.00 for 10 business days in a row to comply, according to the filing.
Gelteq, a Melbourne-based biotech firm, has its focus on gel-based delivery tech for pharma, consumer health and animal health. The stock dropped hard off its $2.01 intraday high but still trades comfortably above Wednesday’s close. Traders are watching where Gelteq closes, the trading volume, and if the company puts out anything new on its investor-relations site after its latest updates.
